Reviving the promise of transcription factor Nrf2-based therapeutics for kidney diseases

Kidney International

Volumn 88, Issue 6, 2015, Pages 1217-1218

  Noel, Sanjeev ^a   Hamad, Abdel R A ^a   Rabb, Hamid ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE METHYL; CHALCONE DERIVATIVE; GLUTATHIONE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LYCOPENE; OLEANOLIC ACID; PLACEBO; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESVERATROL; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFECT; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY CELL; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEOMICS; RENAL PROTECTION; REVIEW; TRANSCRIPTOMICS;

EID: 84949895799     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.328     Document Type: Article

References (11)

1. Liu M, Grigoryev DN, Crow MT et al. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 2009; 76: 277-285
2. Pedruzzi LM, Cardozo LF, Daleprane JB et al. Systemic inflammation and oxidative stress in hemodialysis patients are associated with down-regulation of Nrf2. J Nephrol 2015; 28: 495-501
3. Leonard MO, Kieran NE, Howell K et al. Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemiareperfusion injury. FASEB J 2006; 20: 2624-2626
4. Liu M, Reddy NM, Higbee EM et al. The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice. Kidney Int 2014; 85: 134-141
5. Wu QQ, Wang Y, Senitko M et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPAR, and HO-1. Am J Physiol Renal Physiol 2011; 300: F1180-F1192
6. Pergola PE, Raskin P, Toto RD et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336
7. Chin MP, Reisman SA, Bakris GL et al. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol 2014; 39: 499-508
8. Shelton LM, Lister A, Walsh J et al. Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney. Kidney Int 2015; 88: 1261-1273
9. Noel S, Martina MN, Bandapalle S et al. T lymphocyte-specific activation of Nrf2 protects from AKI. J Am Soc Nephrol 2015, (e-pub ahead of print)
10. Noel S, Arend LJ, Bandapalle S et al. Deletion of kelch-like ECH associated protein 1 (Keap1) in kidney epithelial cells causes hydronephrosis in mice. J Am Soc Nephrol 2014; 25: 538A
11. Kinch L, Grishin NV, Brugarolas J. Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell 2011; 20: 418-420.